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ABS TRACT
Congenital hyperinsulinism (CHI) is the commonest cause of persistent 
hypoglycemia in neonates. Diazoxide is the first-line drug in its treatment, but 
the more severe cases are usually diazoxide-resistant. Recessive ABCC8 and 
KCNJ11 mutations are responsible for most (82%) of the severe diazoxide-
unresponsive CHI. Oral nifedipine has been effective in isolated cases of 
CHI. Successful treatment of diazoxide-unresponsive CHI with a combination 
of octreotide and nifedipine has been reported in a single isolated case so 
far. We report here a case of diazoxide-resistant CHI due to homozygous 
ABCC8 nonsense mutation. In this case, hypoglycaemia uncontrolled 
by pancreatectomy and octreotide alone showed a good response to a 
combination of nifedipine and octreotide. Octreotide was tapered off by 
one year age and thereafter the child is euglycaemic on oral nifedipine 
alone. Continuous glucose monitoring sensor was used as an aid to monitor 
glycaemic control and was found to be a safe and reliable option reducing the 
number of needle-pricks in small children.
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Introduction
Congenital hyperinsulinism (CHI) comprises a 
heterogeneous group of genetic disorders with the common 
finding of recurrent episodes of hyperinsulinemic hypoglycemia 
due to an inappropriate secretion of insulin by the pancreatic 
β-cells. It is the commonest cause of persistent hypoglycemia 
in the neonatal and infancy periods. The incidence is estimated 
at 1/50000 live births, but may be as high as 1/2500 in 
countries where consanguinity is common (1). Mutations in 
the ABCC8 and KCNJ11 genes, which encode subunits of the 
ATP-sensitive potassium channel (KATP) in the pancreatic β-cell, 
are identified in approximately 40 to 45% of these patients 
and are responsible for most (82%) of the severe diazoxide-
unresponsive CHI. Mutations have been identified in seven 
other genes in approximately 5 to 10% of the cases, while 
the genetic etiology of the rest is still unknown. In western 
countries, 45-60% of diazoxide-unresponsive CHI are focal 
forms, whereas 40-45% are diffuse forms (1,2,3).
In CHI, a high-glucose infusion rate is required to prevent 
hypoglycemia. The hypoglycemia responds to exogenous 
glucagon, since glucagon stimulates glycogen breakdown 
and gluconeogenesis. As insulin inhibits lipolysis, there is 
no compensatory generation of ketone bodies which could 
serve as an alternative fuel for the brain to protect it from 
hypoglycemia (1). Rapid diagnosis and prompt management 
of the hypoglycaemia are vital in preventing brain damage and 
mental retardation (4). The severity of CHI may be evaluated by 
the rate of glucose infusion required to maintain normoglycemia 
(1), though this may not necessarily be always true.
The first-line drug in the treatment of CHI is diazoxide 
(1,5). However, it is generally ineffective for the most severe, 
neonatal-onset, recessive and focal forms of KATP-CHI (5). 
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Octreotide and glucagon can be used in patients who show no 
response to diazoxide. Calcium-channel blockers, like nifedipine, 
showed a clear efficiency in mouse models (6) and in isolated 
case reports (7,8,9,10). While most HI centers did not observe 
any response to nifedipine in large series of patients (1), it has 
been shown to be an effective treatment in a small number 
of patients with diazoxide-unresponsive CHI (7,8,9,10). The 
literature regarding the use of nifedipine in CHI is limited and 
conflicting and there is controversy about the dosage, side-
effects and efficacy of short- versus long-acting formulations.
Here we report a case of a baby girl with diazoxide-
unresponsive CHI treated with subcutaneous (S/c) octreotide 
and oral nifedipine for persistent hypoglycaemia after partial 
pancreatectomy. At 11/2 years, the patient is now on oral 
nifedipine only for past 6 months after octreotide was tapered 
off and stopped by 1 year of age. Genetic testing of the 
child showed that she is a compound heterozygote for an 
ABCC8 missense mutation. We also found continuous glucose 
monitoring sensor (CGMS) to be a safe, effective way of home 
monitoring in very small children and it reduced the number of 
needle-pricks for glucose-monitoring particularly when dosage 
of medications needed tapering or titration, in addition to 
instilling confidence in parents worried about asymptomatic 
hypoglycaemia regarding home management of the condition.
Case Report
An 11-day-old baby girl was referred with history of 
recurrent convulsions and severe, persistent hypoglycaemia. 
The baby was born of non-consanguineous marriage to a non-
diabetic mother by elective Caesarean section at term. Baby 
was macrosomic (birth weight-4.7 kg) with no dysmorphic 
features. On admission, the patient needed a glucose infusion 
of 24 mg/kg/min via central line to maintain euglycaemia.
Investigations revealed inappropriately high levels of serum 
insulin and C-peptide levels during hypoglycemic episodes 
(glucose <40 mg/dL) [insulin - 66.4 µIU/mL (normal - 4 to 
24.9) and C-peptide level - 9.8 ng/mL (normal - 1.1 to 3.6 
ng/mL)]. Serum growth hormone, thyroid and cortisol levels 
were normal. A glucagon response was positive i.e. an increase 
of glucose level >50 mg/dL within 30 minutes of glucagon 
injection was recorded. Magnetic resonance imaging scan of 
the abdomen did not reveal any localized lesion in the pancreas. 
Based on these findings, a diagnosis of CHI was made and 
genetic testing of the child and both parents showed that she 
is a compound heterozygote for an ABCC8 missense mutation, 
p.R1419C (c.4255C>T) and a deletion of ABCC8 exon 3 (c.291-
?_412+?del) thus confirming diffuse disease. Recommended 
medications were either not well-tolerated or difficult to procure. 
Surgery in the form of a limited subtotal pancreatectomy was 
discussed with the parents and performed.
Histopathological examination after the pancreatectomy 
confirmed the diagnosis of CHI due to diffuse lesion.
Post-operatively after an initial drop, glucose requirement 
gradually increased by day 4 to 20 mg/kg/min, only marginally 
less than pre-operative requirements. Oral diazoxide had not 
been tolerated causing severe, persistent vomiting. Octreotide 
was started S/cly at a dose of 5 µg/kg/d 8 hrly with doses being 
gradually increased to 30 µg/kg/d 6 hrly. By day 40, the baby 
was maintaining euglycaemia on full enteral 2 hrly feeds and 
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Figure 1. CGMS data showing euglycaemia (glucose >60mg/
dl) after starting oral nifedipine along with s/c octreotide in post-
pancreatectomy patient with CHI  
Figure 2. CGMS data at 11/2 year age showing hypoglycaemia on 
tapering off oral nifedipine with recovery on re-starting nifedipine in 
previous dosage
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S/c octreotide (30 µg/kg/day) without glucose infusion and was 
discharged to home.
However, within 48 hours the baby was readmitted with 
feeding problems and episodes of symptomatic hypoglycaemia. 
In hospital, on reassessing the situation, we felt that in 
order to avoid dangerous pre-feed dips of blood glucose 
and early morning hypoglycaemia, a small but continuous 
infusion of iv glucose at the rate 1 to 1.5 mg/kg/min was still 
required. Calorie-densers (like coconut oil and human milk 
fortifiers) were added to feeds which though well-tolerated 
did not stop hypoglycaemic episodes. Re-surgery, i.e. sub-total 
pancreatectomy, was not considered as an option. A trial of oral 
nifedipine was given which was started at the lowest dose and 
gradually increased to 0.8 mg/kg/day over the next 6 days. This 
was well-tolerated with no side effects like hypotension and 
the baby was euglycaemic with no pre-feed or early morning 
hypoglycaemia on a combination of oral nifedipine and S/c 
octreotide. After extensive parent education, the baby was 
re-discharged with a CGMS probe in situ and CGM was done at 
home for the next few days. On follow-up, CGMS data showed 
good glycaemic control with interstitial fluid glucose levels 
never dropping below 40 mg/dL (vide Figure 1).
After 4 months, S/c octreotide was gradually tapered off 
and stopped by one year of age. The child thereafter maintained 
euglycaemia on oral nifedipine only. Follow-up visits were 
difficult to arrange and at 11/2 years of age, the baby was 
admitted to determine if the dose of nifedipine also needed 
tapering. A CGMS monitor was inserted and oral nifedipine was 
tapered under supervision. However, following a hypoglycaemic 
episode, nifedipine was restarted in the previous dosage of 
0.8 mg/kg/day. A high insulin level during the hypoglycaemic 
episode (insulin-19 µIU/mL when lab glucose was 29 mg/dL) 
confirmed the persistent hyperinsulinaemic state. CGMS data 
after readjusting nifedipine dosage to previous levels shows 
good glycaemic control (vide Figure 2).
Discussion
CHI can occur as a result of mutations in the subunits that 
form the KATP in pancreatic β-cells which modulates insulin 
secretion from the β-cells, namely the plasma membrane 
sulfonylurea receptor, ABCC8 and its associated inwardly 
rectifying potassium channel (KIR6.2) KCNJ11. Drugs which 
act on KATP channels, such as diazoxide, seem to need intact 
ABCC8 to be able to exert their effects (2). There is a keen 
interest to try and identify the exact genetic locus causing a 
particular abnormality in the β-cell in the hope that it may help 
in choosing the right therapeutic agent. However, mutation 
analysis of 13 patients with CHI of varying severity did not find 
mutations in the ABCC8 gene to be predictive of response to 
drugs (2).
Calcium-channel blockers, like nifedipine, have been 
reported to be effective in isolated case reports (7,8,9,10). 
Octreotide is a long-acting analogue of somatostatin, which 
has inhibitory effects on the release of insulin from pancreatic 
β cells. It has been successfully used in the short and long-
term management of some patients with CHI in combination 
with frequent feeding (11). Another case has been reported to 
be successfully treated with a combination of nifedipine and 
octreotide (10). Glaser et al (12) reported a patient with CHI 
who was treated with octreotide and amlodipine (a calcium-
channel blocker). It has been speculated that nifedipine, an 
L-type calcium-channel blocker and octreotide, which inhibits 
the Ca2+ entry into the pancreatic β-cells via voltage-operated 
Ca2+ channels of the L-type leading to suppression of insulin 
secretion (13), may have an additive effect (10).
The points of interest in our patient are: a) She was born 
of non-consanguineous marriage and had severe CHI inherited 
as autosomal recessive pattern; both parents being carriers. 
The maternally inherited p.R1419C mutation was detected 
by Sanger sequencing and has been reported previously (14). 
Dosage analysis of the ABCC8 gene by Multplex Ligation-
Dependent Probe Amplification identified the paternally 
inherited heterozygous deletion of exon 3 (c.291-?_412+?del). 
The condition is rare in this population group in Asia where 
consanguineous marriages are uncommon. b) We were forced 
by circumstances to do a suboptimal pancreatectomy after 
which hypoglycemia persisted. Post-operatively, oral nifedipine 
was successful in controlling hypoglycaemia which remained 
uncontrolled by partial pancreatectomy and octreotide in a 
diazoxide-resistant case of CHI. Side-effects were not noted 
at our dose of 0.8 mg/kg/day. At present, at 11/2 yrs age, 
glycaemic control is maintained by oral nifedipine, while its 
withdrawal precipitates hypoglycemia. c) Use of nifedipine in 
adjunct to octreotide seemed to have an additive effect and 
it strengthens the speculation that calcium-channel blockers 
may work synergistically with octreotide, though the exact 
molecular mechanism is unclear. d) CGMS monitoring at home 
was found to be a feasible, safe option to monitor glycaemic 
control in a small baby. It reduced the need of frequent needle-
pricks to monitor blood glucose and helped to allay parental 
anxiety regarding asymptomatic hypoglycaemic episodes.
Oral nifedipine was effective and well-tolerated at doses of 
0.8 mg/kg/day in our patient. Hypotension is a potential side-
effect (15) and has been reported at doses above 0.5 mg/kg/
day (10). It seems that the therapeutic window of nifedipine is 
variable and hence needs individual customization and needs 
close monitoring during start of therapy. Short-acting nifedipine 
was cheap and easily available in soft gel capsules for adult 
use, but no liquid formulation was available. The capsulated 
short-acting form was known to be uns, photosensitive and 
heat-labile and had to be removed from the capsule and made 
up to proper strength before each dose.
Though the manufacturer does not recommend use of 
the CGMS to diagnose hypoglycemia, it has been used 
previously to detect hypoglycaemia and help titrate the 
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dextrose concentration and other drugs (16,17). 24-hour trends 
have helped in better timing of medications so as to minimize 
the number of asymptomatic hypoglycaemic episodes. In our 
patient, the post-surgery CGMS data helped in documentation 
of euglycemia following the initiation of nifedipine therapy 
in adjunct to S/c octreotide and was particularly helpful in 
reassuring the parents on follow-up. We used CGMS data again 
at 11/2 years of age to document persistent hyperinsulinaemic 
state as well as good glycaemic control with oral nifedipine. In 
younger populations in whom the symptoms of hypoglycaemia 
are difficult to recognize and can be potentially life-threatening, 
CGMS can be an option to identify hypoglycemic episodes 
instead of frequent finger prick measurements. However, for 
us, a limiting factor was the cost of the device. Also as the 
sensor becomes old, there is increasing mismatch between 
the values of finger prick method (CBG) and CGM values. 
Though according to a meta-analysis (18), the sensor can give 
relatively accurate results for up to seven days; in our case, 
CGMS correlated well with CBG values till 4 days of insertion.
In conclusion, our case of diazoxide-resistant hyperinsulinism 
due to compound heterozygous ABCC8 mutations showed 
a good response to a combined treatment of nifedipine 
and octreotide. Further studies are required to evaluate the 
nifedipine effect and its dose range in patients with CHI.
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